Why the study?
Recent RCTs showed prognostic cardiovascular benefits of SGLT2 inhibitors in diabetes, motivating an evaluation of their role in heart failure regardless of baseline diabetes status.
Do SGLT2 inhibitors reduce mortality and cardiovascular events in patients with heart failure regardless of baseline diabetes status?
Comparison
SGLT2 inhibitors vs comparator
Design
Systematic review and meta-analysis
Key result
SGLT2 inhibitors reduced the risk of all-cause mortality (HR 0.83; 95% CI 0.75-0.91) and hospitalization for HF or CV death (HR 0.72; 95% CI 0.66-0.78) in patients with heart failure.
Authors
Loading...
Supports SGLT2 inhibitor use across heart failure regardless of diabetes; confirms mortality and event reductions in meta-analysis of 8 RCTs.
Meta-Analysis (n=13,275)
Do SGLT2 inhibitors reduce mortality and cardiovascular events in patients with heart failure regardless of baseline diabetes status?
Hazard Ratio: 0.83 (95% CI 0.75–0.91)
SGLT2 inhibitors significantly reduce all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with heart failure, regardless of their baseline diabetes status.
Tsampasian et al. (2021) conducted a meta-analysis in Heart failure (n=13,275). SGLT2 inhibitors was evaluated on All-cause mortality (HR 0.83, 95% CI 0.75-0.91). SGLT2 inhibitors reduced the risk of all-cause mortality (HR 0.83; 95% CI 0.75-0.91) and hospitalization for HF or CV death (HR 0.72; 95% CI 0.66-0.78) in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: